<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJU</journal-id><journal-title-group><journal-title>Open Journal of Urology</journal-title></journal-title-group><issn pub-type="epub">2160-5440</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/oju.2024.144022</article-id><article-id pub-id-type="publisher-id">OJU-132745</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Prostatic Adenomectomy and Comorbidities: Frequency and Management at the Urology Department of the Ignace Deen National Hospital in Conakry
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Demba</surname><given-names>Cisse</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Alpha</surname><given-names>Oumar Barry</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Morlaye</surname><given-names>Fatoumata Bangoura</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Alimou</surname><given-names>Diallo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mamadou</surname><given-names>Dian Bah</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Youssouf</surname><given-names>Keita</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Daouda</surname><given-names>Kant&amp;#233;</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Thierno</surname><given-names>Mamadou Oury Diallo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mamadou</surname><given-names>Bissiriou Bah</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mamadou</surname><given-names>Diawo Bah</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abdoulaye</surname><given-names>Bobo Diallo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Oumar</surname><given-names>Raphiou Bah</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Maitre-Assistant &amp;amp;#224; la Facult&amp;amp;#233; des Sciences et Techniques de la Sant&amp;amp;#233;, Universit&amp;amp;#233; Gamal Abdel Nasser de Conakry, Conakry, Guin&amp;amp;#233;e</addr-line></aff><pub-date pub-type="epub"><day>17</day><month>04</month><year>2024</year></pub-date><volume>14</volume><issue>04</issue><fpage>217</fpage><lpage>226</lpage><history><date date-type="received"><day>13,</day>	<month>February</month>	<year>2024</year></date><date date-type="rev-recd"><day>23,</day>	<month>April</month>	<year>2024</year>	</date><date date-type="accepted"><day>26,</day>	<month>April</month>	<year>2024</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  &lt;b&gt;Goal&lt;/b&gt;: To determine the type of comorbidity and highlight the complications of adenomectomy and comorbidities. &lt;b&gt;Material&lt;/b&gt;&lt;b&gt; &lt;/b&gt;&lt;b&gt;and&lt;/b&gt;&lt;b&gt; &lt;/b&gt;&lt;b&gt;Methods&lt;/b&gt;: This is a prospective, descriptive, cross-sectional study lasting six (6) months, from July 1, 2022 to December 31, 2022. Patients with BPH on comorbidity condition taken care of during the study period AND have agreed to participate in the study. &lt;b&gt;Results&lt;/b&gt;: During our study, 49 cases of benign prostatic hypertrophy with comorbidities were collected, representing a frequency of 29%. The average age ranges for the patients were 43 - 70 years. The age group most affected was 70 to 79 years old (38.80%). Nocturnal urinary frequency was the main reason for consultation present in all our patients. The most frequent comorbidity was hypertension, &lt;i&gt;i.e.&lt;/i&gt; 83.70%. The PSA rate between 4 and 10 was the most represented, &lt;i&gt;i.e.&lt;/i&gt; 42.86%. The prostate volume was between 61 and 100 ml in 40.82% of patients. Histology showed that it was a benign adenomatous hypertrophy of the prostate in 85.70% and a prostatic adenomyoma in 14.29%. Trans-bladder adenomectomy alone was the most performed technique, &lt;i&gt;i.e.&lt;/i&gt; 49%, followed by trans urethral resection of the prostate, &lt;i&gt;i.e.&lt;/i&gt; 38.80%. Retention of urine after removal of the catheter was the most observed complication, &lt;i&gt;i.e.&lt;/i&gt; 12.20%. &lt;b&gt;Conclusion&lt;/b&gt;: Benign prostatic hypertrophy with comorbidities constitutes a frequent association. Because their presence can affect effectiveness and lead to complications.
 
</p></abstract><kwd-group><kwd>Prostatic Hypertrophy</kwd><kwd> Comorbidities</kwd><kwd> Conakry University Hospital</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Prostatic adenomectomy is the surgical removal of the prostate adenoma [<xref ref-type="bibr" rid="scirp.132745-ref1">1</xref>] .</p><p>From the age of 50, approximately 50% of men present with lower urinary tract symptoms (LUTS) related to benign prostatic hypertrophy (BPH). This percentage then gradually increases approximately 10% per year until it concerns around 80% of men aged 80 [<xref ref-type="bibr" rid="scirp.132745-ref2">2</xref>] . It constitutes the main cause of obstructive and irritative signs of the lower urinary tract, the development of which can lead, in the final stage, to renal failure [<xref ref-type="bibr" rid="scirp.132745-ref3">3</xref>] .</p><p>Age-related changes in androgens are widely accepted as the primary factors involved in the pathogenesis of BPH. Additionally, ethnicity, type II diabetes, cholesterol, high blood pressure, and obesity have been reported as risk factors [<xref ref-type="bibr" rid="scirp.132745-ref4">4</xref>] .</p><p>Most studies have shown that obesity increases the risk of BPH [<xref ref-type="bibr" rid="scirp.132745-ref5">5</xref>] .</p><p>Although transurethral resection of the prostate and upper adenomectomy remain the reference techniques for the surgical treatment of benign prostatic hypertrophy, the development of microwaves and radio frequency have made it possible to propose alternatives. Urethral prostheses, more recently intraprostatic injection of ethanol and botulinum toxin, have completed the therapeutic arsenal in patients with BPH with comorbidities [<xref ref-type="bibr" rid="scirp.132745-ref6">6</xref>] . Comorbidities in patients with LUTS should be noted when choosing treatment, as their presence may affect long-term efficacy and/or tolerability [<xref ref-type="bibr" rid="scirp.132745-ref7">7</xref>] .</p><p>In France, in 2015, Misrai V et al. reported that more than a million men aged over 50 years are treated for lower urinary tract symptoms related to benign prostatic hyperplasia [<xref ref-type="bibr" rid="scirp.132745-ref8">8</xref>] .</p><p>In the USA, in 2009, Parsons et al. reported at the University of California of 26,000 participants, those with obesity (waist circumference greater than 109 cm) were 38% more likely to undergo BPH surgery than those with a non-obese waist circumference (less than 85%) [<xref ref-type="bibr" rid="scirp.132745-ref5">5</xref>] .</p><p>In China, in 2014, Pan et al. reported that in Sun yet-sun memorial hospital out of 1052 patients with BPH, the prevalence of metabolic syndrome was 39.73% [<xref ref-type="bibr" rid="scirp.132745-ref4">4</xref>] .</p><p>In Togo, in 2018, Botcho G et al. reported that at the Kara University Hospital out of 76 patients who underwent transvesical adenomectomy of the prostate, 72.37% had at least one comorbidity factor with a predominance of arterial hypertension in 33 cases (43.42%) [<xref ref-type="bibr" rid="scirp.132745-ref9">9</xref>] .</p><p>Thus, the frequency of comorbidities and prostatic adenomectomy and the complications they generate motivated this study.</p></sec><sec id="s2"><title>2. Goals</title><p>1) Determine the proportion of adenomectomy with comorbidity.</p><p>2) Determine the different types of comorbidities.</p><p>3) Highlight the complications of BPH with comorbidities.</p></sec><sec id="s3"><title>3. Material and Methods</title><p>This was a prospective, descriptive, cross-sectional study lasting six (6) months, from July 1, 2022 to December 31, 2022. Concerning patients who underwent prostatic adenomectomy associated with one or more comorbidities admitted at the urology-andrology department during the study period.</p><p>The following were used as support for carrying out this study: the register of operating reports; the patients’ medical records and a pre-established investigation form.</p><sec id="s3_1"><title>3.1. Inclusion Criteria</title><p>Patients who underwent prostatic adenomectomy with comorbidity during the study period and who agreed to participate in the study after informed consent were included in this study.</p></sec><sec id="s3_2"><title>3.2. Non-Inclusion Criteria</title><p>Patients received for pathologies other than BPH were not included in our study;</p><p>All patients admitted for BPH and comorbidity who have not undergone surgery;</p><p>All patients who underwent adenomectomy without comorbidity.</p></sec><sec id="s3_3"><title>3.3. Variables</title><p>Our study variables were divided into:</p><p>Epidemiological variables: Proportion; age.</p></sec><sec id="s3_4"><title>3.4. Clinical Variables</title><p>Reasons for consultation: these are the signs and/or symptoms that led the patient to see a doctor. These are: pollakiuria; burning when urinating; urgency, dysuria; the RAUV; the RCIUV; the RCCUV.</p></sec><sec id="s3_5"><title>3.5. Comorbidities</title><p>Presence of one or more disease states associated with adenomectomy: Diabetes; high blood pressure (HTA); cerebrovascular accident (CVA); the Human Immunodeficiency Virus (HIV); chronic renal failure; obesity.</p></sec><sec id="s3_6"><title>3.6. Physical Signs</title><p>These are the signs highlighted by the examining doctor at the consultation including: AEG, lumbar contact, bladder globe, rectal examination data, etc.</p><sec id="s3_6_1"><title>3.6.1. Paraclinical Variables</title><p>Biology: Determination of total serum PSA; Creatininemia; Cytobacteriological examination of urine (ECBU).</p><p>Imaging:</p><p>Reno-vesico-prostatic ultrasound: it allowed us to evaluate the prostate volume. The prostate volume was divided into amplitude slices of 20 cc, an average will be determined as well as the extremes.</p></sec><sec id="s3_6_2"><title>3.6.2. Therapeutic Variable</title><p>The patients were distributed according to the therapeutic class used.</p></sec></sec><sec id="s3_7"><title>3.7. Types of Treatments</title><p>&#183; Transvesical adenomectomy of the prostate: is the surgical removal of the adenoma of the prostate by the transvesical route.</p><p>&#183; Trans-urethral resection of the prostate: Consists of removing the prostate adenoma in small shavings through a resector equipped with a camera under a stream of water and a cold light.</p><p>&#183; Millin (Retro pubic adenomectomy): this is the removal of the prostate via the retro pubic route.</p><p>The Results were Favorable or unfavorable (complications).</p></sec><sec id="s3_8"><title>3.8. Complications</title><p>The complications were classified as follow: Compartment hemorrhage, obstructive renal failure, parietal suppuration, urinary infection, epididymitis orchid, retention of urine after removal of the probe, vesicocutaneous fistula, death.</p></sec><sec id="s3_9"><title>3.9. Ethical Considerations</title><p>- the information was collected anonymously and confidentiality was required;</p><p>- We declare no conflict of interest for the production and dissemination of the results.</p></sec></sec><sec id="s4"><title>4. Results</title><p>Text 1: The proportion: it is the ratio between the number of HBP with comorbidities (49) and the total number of HBP (155) in the department which is 29% (Tables 1-4).</p><p>Text 2: Distribution of patients according to serum creatinine value (<xref ref-type="table" rid="table5">Table 5</xref>).</p><p>The serum creatinine was between 0.6 - 1.4 mg/dl in 38 patients (77.56%); it was greater than 1.4 mg/dl in 11 patients (22.44%).</p><p>Mean serum creatinine: 1.4 &#177; 0.90 with extremes of 0.70 and 6.68 mg/dl.</p><p>Text 3: Histological diagnosis.</p><p>We had 42 cases of benign adenomatous hyperplasia of the prostate (85.71%) and 07 cases of prostatic adenomyoma (14.29%) (Tables 6-8).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Distribution of patients according to age group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Years</th><th align="center" valign="middle" >Effectifs</th><th align="center" valign="middle" >Pourcentage</th></tr></thead><tr><td align="center" valign="middle" >50 - 59 years</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >12.2</td></tr><tr><td align="center" valign="middle" >60 - 69 years</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >28.6</td></tr><tr><td align="center" valign="middle" >70 - 79 years</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >38.8</td></tr><tr><td align="center" valign="middle" >≥80 years</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >20.4</td></tr><tr><td align="center" valign="middle" >TOTAL</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><p>Middle age: 70.43 years &#177; 8.74, Extreme: 50 and 85 years.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Breakdown of patients by reason for consultation</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Reason for consultation</th><th align="center" valign="middle" >Number</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Nocturnal pollakiuria</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >77.55</td></tr><tr><td align="center" valign="middle" >Diurnal pollakiuria</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >46.94</td></tr><tr><td align="center" valign="middle" >Post void volume</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >85.71</td></tr><tr><td align="center" valign="middle" >Dysuria</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >85.6</td></tr><tr><td align="center" valign="middle" >Urgenturia</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >67.3</td></tr><tr><td align="center" valign="middle" >Chronic incomplete urinary retention</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >46.9</td></tr><tr><td align="center" valign="middle" >Chronic complete urinary retention</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >30.6</td></tr><tr><td align="center" valign="middle" >Urinary burning</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >30.6</td></tr><tr><td align="center" valign="middle" >Hematuria</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.0</td></tr></tbody></table></table-wrap><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Distribution of patients by comorbidity</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Comorbidity</th><th align="center" valign="middle" >Numbers</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >High blood pressure</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >83.7</td></tr><tr><td align="center" valign="middle" >Diabetes</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >18.4</td></tr><tr><td align="center" valign="middle" >Chronic renal failure</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >6.1</td></tr><tr><td align="center" valign="middle" >Stroke</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >4.1</td></tr><tr><td align="center" valign="middle" >Obesity</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.0</td></tr><tr><td align="center" valign="middle" >HIV</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.0</td></tr></tbody></table></table-wrap><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Distribution of patients by comorbidity association</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Association of comorbidities</th><th align="center" valign="middle" >Numbers</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >High blood pressure + Diabetes</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >10.2</td></tr><tr><td align="center" valign="middle" >High blood pressure + stroke</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >4.08</td></tr><tr><td align="center" valign="middle" >HIV + Obesity</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.04</td></tr></tbody></table></table-wrap><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Distribution of patients according to the germ isolated at ECBU</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >ECBU result</th><th align="center" valign="middle" >Number</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Culture sterile</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >42.9</td></tr><tr><td align="center" valign="middle" >E. coli</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >22.4</td></tr><tr><td align="center" valign="middle" >Staphylococcus aureus</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >12.2</td></tr><tr><td align="center" valign="middle" >Staphylococcus lentus</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >8.2</td></tr><tr><td align="center" valign="middle" >Klebssiela pneumoniae</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >4.1</td></tr><tr><td align="center" valign="middle" >Pneumococcus</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.0</td></tr><tr><td align="center" valign="middle" >Enterobacter aerogens</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.0</td></tr><tr><td align="center" valign="middle" >Proteus microbilis</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.0</td></tr><tr><td align="center" valign="middle" >Pseudomonas aeroginosa</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.0</td></tr><tr><td align="center" valign="middle" >Staphylococcus capitis</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.0</td></tr><tr><td align="center" valign="middle" >TOTAL</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Distribution of patients according to surgical treatment</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Surgical treatment</th><th align="center" valign="middle" >Number</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Transvesical adenomectomy</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >48.98</td></tr><tr><td align="center" valign="middle" >TURP</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >40.8</td></tr><tr><td align="center" valign="middle" >Retropubic adenomectomy</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >10.2</td></tr><tr><td align="center" valign="middle" >TOTAL</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> Distribution of patients according to complications</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Complications</th><th align="center" valign="middle" >Numbers</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Surgical site infection</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >12.2</td></tr><tr><td align="center" valign="middle" >Urine retention after catheter removal</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >10.2</td></tr><tr><td align="center" valign="middle" >Vesico-cutaneous fistula</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >8.2</td></tr><tr><td align="center" valign="middle" >Acute epididymitis</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >6.1</td></tr><tr><td align="center" valign="middle" >Urinary tract infection</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >4.1</td></tr></tbody></table></table-wrap><table-wrap id="table8" ><label><xref ref-type="table" rid="table8">Table 8</xref></label><caption><title> Correlation between comorbidities and age groups</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  ></th><th align="center" valign="middle"  colspan="4"  >Age groups</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle"  colspan="2"   rowspan="2"  >Comorbidities</td><td align="center" valign="middle"  colspan="2"  >Age ≤ 70 ans</td><td align="center" valign="middle"  colspan="2"  >Age &gt; 70 ans</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >P</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Diabetes</td><td align="center" valign="middle" >Oui</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >77.8</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >42.5</td><td align="center" valign="middle"  rowspan="2"  >0.060</td></tr><tr><td align="center" valign="middle" >Non</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >22.2</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >57.5</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >HTA</td><td align="center" valign="middle" >Oui</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >46.3</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >53.7</td><td align="center" valign="middle"  rowspan="2"  >0.327</td></tr><tr><td align="center" valign="middle" >Non</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >62.5</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >37.5</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Renal failure</td><td align="center" valign="middle" >Oui</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >66.7</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >47.8</td><td align="center" valign="middle"  rowspan="2"  >0.484</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >33.3</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >52.2</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >HIV</td><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.0</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >50.0</td><td align="center" valign="middle"  rowspan="2"  >0.510</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >50.0</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Stroke</td><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >50.0</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >48.9</td><td align="center" valign="middle"  rowspan="2"  >0.745</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >50.0</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >51.1</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Obesity</td><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >50.0</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >48.9</td><td align="center" valign="middle"  rowspan="2"  >0.745</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >50.0</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >51.1</td></tr></tbody></table></table-wrap></sec><sec id="s5"><title>5. Discussion</title><p>From July 1 to December 31, 2022, we carried out a prospective descriptive study in 49 patients hospitalized and operated for benign prostatic hypertrophy with comorbidity in the Urology-Andrology department of the Ignace Deen National Hospital.</p><p>The high cost of the pathological examination did not allow us to have a larger number of patients.</p><sec id="s5_1"><title>5.1. AGE</title><p>The average age of our patients was 70.43 years &#177; 8.74. The most represented age group was 70 - 79 years. This result is comparable to those of Bagayogo et al. [<xref ref-type="bibr" rid="scirp.132745-ref10">10</xref>] in Senegal in 2018 at the Aristide Le Dantec University Hospital who reported that the average age of patients was 70.9 &#177; 9.2 years with a predominance in the 70 to 79 age group.</p><p>On the other hand, close to that of Botcho G et al. [<xref ref-type="bibr" rid="scirp.132745-ref9">9</xref>] in Togo in 2018 at the Kara University Hospital who reported that patients aged 60 to 69 years were the most affected with an average of 69.3 years and extremes of 42 to 98 years. The occurrence of prostate pathologies over the ages of 50 would explain this predominance.</p></sec><sec id="s5_2"><title>5.2. Reasons for Consultations</title><p>The reasons for consultations were dominated by nocturnal urinary frequency followed respectively by day time urinary frequency and incomplete bladder emptying. This result is comparable to that of Robert G et al. [<xref ref-type="bibr" rid="scirp.132745-ref2">2</xref>] in France in 2018 which showed that the most frequently reported symptoms were respectively nocturnal urinary frequency (present in 48.6% of patients), the presence of terminal drops (14.2%), and the sensation of emptying incomplete bladder (13.5%). This could be explained by the fact that lower urinary tract symptoms occur more often in men in their fifties.</p></sec><sec id="s5_3"><title>5.3. Comorbidities</title><p>Regarding comorbidities, high blood pressure was the most common, followed by diabetes. Our results are in the same direction as those of Botcho G et al. [<xref ref-type="bibr" rid="scirp.132745-ref9">9</xref>] in Togo in 2018 who reported in their study carried out on 73 patients, 55 patients (72.37%) had at least one comorbidity factor with a predominance of arterial hypertension (hypertension) in 33 cases (43, 42%). Other comorbidity factors were diabetes in 19 cases (25%). This relatively high hypertension rate would explain the increasing incidence of cardiovascular diseases occurring with age after fifty.</p></sec><sec id="s5_4"><title>5.4. PSA Rate</title><p>Regarding the PSA level, almost half of our patients had a level between 4 and 10 ng/ml. Our study contrasts with that of Bagayogo et al. [<xref ref-type="bibr" rid="scirp.132745-ref10">10</xref>] in Senegal in 2018 who found that the PSA level was greater than 10 ng/ml in the majority of their patients, i.e. 61.1%. The acute and chronic retention of urine and in addition a large prostate volume encountered in most of our patients would explain the elevation in the total PSA level.</p></sec><sec id="s5_5"><title>5.5. Prostatic Volume</title><p>Ultrasound was systematic in all our patients. We found that prostate volume varied from 31 ml to 223 ml with an average of 84.141. Our data is close to that of Botcho G et al. [<xref ref-type="bibr" rid="scirp.132745-ref9">9</xref>] in Togo in 2018 who showed that prostate ultrasound had found a prostate volume which varied from 35 ml to 285 ml with an average of 104.7 ml. Our ultrasound results on prostate volume suggested that the majority of our patients had a fairly high prostate volume.</p></sec><sec id="s5_6"><title>5.6. ECBU Result</title><p>Compared to the isolation of Escherichia Coli, our study is inferior to that of Adakal O et al. [<xref ref-type="bibr" rid="scirp.132745-ref3">3</xref>] in Niger in 2021 who reported in their series that Escherichia Coli was isolated in 65.5% of urine cultures. Bagayogo et al. [<xref ref-type="bibr" rid="scirp.132745-ref10">10</xref>] in Senegal in 2018 showed that the cytobacteriological examination of urine (ECBU) revealed a urinary infection in half of the patients, i.e. 50%. Escherichia coli and Cytrobacter freundi were the most incriminated germs. It would be beneficial for these infections to benefit from early diagnosis and effective management to avoid associated infectious complications.</p></sec><sec id="s5_7"><title>5.7. Support</title><p>Speaking of the management, trans-bladder adenomectomy of the prostate took first place followed by trans-urethral resection of the prostate. Our data can be superimposed on that of Debbagh A et al. [<xref ref-type="bibr" rid="scirp.132745-ref11">11</xref>] in Morocco in 2002 who showed in their series that transvesical adenomectomy was first (50.4%) followed by endoscopic resection (49.6%). The presentation of large prostate volumes and the high cost of equipment would explain this result.</p></sec><sec id="s5_8"><title>5.8. Complications</title><p>In our study, complications were dominated by surgical site infection and urine retention after removal of the catheter. Our result is contrary to that of MB Diallo et al. [<xref ref-type="bibr" rid="scirp.132745-ref12">12</xref>] in Guinea in 2001 who showed in their study that the first complication was vesicocutaneous fistula 15.6%, followed by epididymitis orchitis 11.5%.</p></sec><sec id="s5_9"><title>5.9. Duration of Hospitalization</title><p>In our study the average length of hospitalization was 9 days with extremes of 5 and 20 days. Our result is superimposable to that of Botcho G et al. [<xref ref-type="bibr" rid="scirp.132745-ref9">9</xref>] in Togo in 2018 who showed in their study that the average duration of hospitalization was 9 days with extremes of 5 to 21 days.</p><p>Infection of surgical wounds associated with diabetes contributed to the prolongation of the duration of hospitalization days.</p></sec><sec id="s5_10"><title>5.10. Correlation between Comorbidities and Complications</title><p>Diabetes was statistically associated with the occurrence of surgical site infection with a p-value of 0.003. This association could be explained by the fact that diabetes promotes infections.</p></sec></sec><sec id="s6"><title>6. Conclusions</title><p>Benign prostatic hypertrophy and comorbidities are a frequent association in urology. Comorbidities should be noted when choosing treatment, as their presence may affect long-term effectiveness and/or tolerability.</p><p>Comorbidities were dominated by high blood pressure and diabetes. The main complications were surgical site infection and bladder urine retention after removal of the urethral catheter. Diabetes was statistically associated with the occurrence of surgical site infection.</p></sec><sec id="s7"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s8"><title>Cite this paper</title><p>Cisse, D., Barry, A.O., Bangoura, M.F., Diallo, A., Bah, M.D., Keita, Y., Kant&#233;, D., Diallo, T.M.O., Bah, M.B., Bah, M.D., Diallo, A.B. and Bah, O.R. (2024) Prostatic Adenomectomy and Comorbidities: Frequency and Management at the Urology Department of the Ignace Deen National Hospital in Conakry. Open Journal of Urology, 14, 217-226. https://doi.org/10.4236/oju.2024.144022</p></sec></body><back><ref-list><title>References</title><ref id="scirp.132745-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Peyronnet, B., Seisen, T., Ph&amp;#233;, V., Misrai, V., de la Taille, A. and Roupret, M. (2016) Symptomes du bas appareil urinaire secondaire a une hyperplasie benigne de la prostate et dysfonction erectile. &lt;i&gt;La Presse M&amp;#233;dicale&lt;/i&gt;&lt;i&gt;,&lt;/i&gt; 46, 145-153. &lt;br&gt;https://doi.org/10.1016/j.lpm.2016.09.002 </mixed-citation></ref><ref id="scirp.132745-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Robert, G., De La Taille, A. and Descazeaud, A. (2018) Donn&amp;#233;es &amp;#233;pid&amp;#233;miologiques en rapport avec la prise en charge de l&amp;#8217;HBP. &lt;i&gt;Progr&amp;#232;s en Urologie&lt;/i&gt;, 28, 803-812. &lt;br&gt;https://doi.org/10.1016/j.purol.2018.08.005 </mixed-citation></ref><ref id="scirp.132745-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Adakal, O., Rouga, M.M., Abdoulaye, M.B., Adamou, H., Maikassoua, M., Mounkeila, I., &lt;i&gt;et al.&lt;/i&gt; (2021) Hypertrophie B&amp;#233;nigne de la Prostate au Centre Hospitalier R&amp;#233;gional de Maradi: Aspects Cliniques, Th&amp;#233;rapeutiques et Pronostiques. &lt;i&gt;Health Sciences&lt;/i&gt;&lt;i&gt; &lt;/i&gt;&lt;i&gt;and Disease&lt;/i&gt;, 22, 93-97.</mixed-citation></ref><ref id="scirp.132745-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Pan, J.G., Jiang, C., Luo, R. and Zhou, X. (2014) Association of Metabolic Syndrome and Benign Prostatic Hyperplasia in Chinese Patients of Different Age Decades. &lt;i&gt;Ur&lt;/i&gt;&lt;i&gt;o&lt;/i&gt;&lt;i&gt;logia&lt;/i&gt;&lt;i&gt; Internationalis&lt;/i&gt;, 93, 10-16. &lt;br&gt;https://doi.org/10.1159/000354026 </mixed-citation></ref><ref id="scirp.132745-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Parsons, J.K., Sarma, A.V., McVary, K. and Wei, J.T. (2009) Obesity and Benign Prostatic Hyperplasia: Clinical Connections, Emerging Etiological Paradigms and Future Directions. &lt;i&gt;Journal of Urology&lt;/i&gt;, 182, S27-S31. &lt;br&gt;http://www.jurology.com/doi/10.1016/j.juro.2009.07.086 &lt;br&gt;https://doi.org/10.1016/j.juro.2009.07.086 </mixed-citation></ref><ref id="scirp.132745-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Barry Delongchamps, N., Robert, G., Descazeaud, A., Cornu, J.-N., Azzouzi, A.R., Haillot, O., &lt;i&gt;et al.&lt;/i&gt; (2012) Traitement chirurgical de l&amp;#8217;hyperplasie b&amp;#233;nigne de la prostate par thermoth&amp;#233;rapie et autres techniques &amp;#233;mergentes&amp;#8239;: Revue de litt&amp;#233;rature du CTMH de l&amp;#8217;AFU. &lt;i&gt;Progr&amp;#232;s en Urologie&lt;/i&gt;, 22, 87-92.&lt;br&gt;https://doi.org/10.1016/j.purol.2011.08.029 </mixed-citation></ref><ref id="scirp.132745-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Hoke, G.P. (2008) &amp;#201;pid&amp;#233;miologie de l&amp;#8217;hyperplasie b&amp;#233;nigne de la prostate et Comorbidit&amp;#233;s dans les populations de minorit&amp;#233;s raciales et ethniques. &lt;i&gt;The American Jou&lt;/i&gt;&lt;i&gt;r&lt;/i&gt;&lt;i&gt;nal of Medicine&lt;/i&gt;, 121, 8. &lt;br&gt;https://doi.org/10.1016/j.amjmed.2008.05.021 </mixed-citation></ref><ref id="scirp.132745-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Misra&amp;#239;, V., Barry Delongchamps, N., Lebdai, S., Azzouzi, A.R., Benchikh, A., Cornu, J.N., &lt;i&gt;et al.&lt;/i&gt; (2015) Complications graves et inattendues de la chirurgie de l&amp;#8217;hyperplasie b&amp;#233;nigne de prostate&amp;#8239;: R&amp;#233;sultats de l&amp;#8217;enqu&amp;#234;te du CTMH aupr&amp;#232;s des urologues de l&amp;#8217;AFU. &lt;i&gt;Progr&amp;#232;s en Urologie&lt;/i&gt;, 25, 583-589. &lt;br&gt;https://doi.org/10.1016/j.purol.2015.06.006 </mixed-citation></ref><ref id="scirp.132745-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Botcho, G., Kpatcha, T.M., Tengue, K., Dossouvi, T., Sewa, E.V., Simlawo, K., &lt;i&gt;et al.&lt;/i&gt; (2018) Morbidit&amp;#233; et mortalit&amp;#233; apr&amp;#232;s ad&amp;#233;nomectomies prostatiques par voie transv&amp;#233;sicale au CHU Kara (Togo). &lt;i&gt;African Journal of Urology&lt;/i&gt;, 24, 353-358.&lt;br&gt;https://doi.org/10.1016/j.afju.2018.01.008 </mixed-citation></ref><ref id="scirp.132745-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Bagayogo, N., Faye, M., Sine, B., Sarr, A., N&amp;#8217;Diaye, M., N&amp;#8217;Diath, A.,&lt;i&gt; et al.&lt;/i&gt; (2021) Hypertrophie b&amp;#233;nigne de la prostate geante: aspect &amp;#233;pid&amp;#233;miologique, clinique et th&amp;#233;rapeutique. &lt;i&gt;Journal &lt;/i&gt;&lt;i&gt;Africain&lt;/i&gt; &lt;i&gt;d&lt;/i&gt;&amp;#8217;&lt;i&gt;U&lt;/i&gt;&lt;i&gt;rologie&lt;/i&gt;, 27, 49-55. &lt;br&gt;https://doi.org/10.21608/afju.2021.9359 </mixed-citation></ref><ref id="scirp.132745-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Debbagh, A., Dahami, Z., Fekak, H., Joual, A., Bennami, S., Elmrini, M., &lt;i&gt;et al.&lt;/i&gt; (2002) Corr&amp;#233;lation anatomopathologique dans l&amp;#8217;hypertrophie b&amp;#233;nigne de la prostate a propos d&amp;#8217;une s&amp;#233;rie de 220 cas. &lt;i&gt;Annals of Urological&lt;/i&gt;, 36, 190-195.&lt;br&gt;https://doi.org/10.1016/S0003-4401(02)00098-0 </mixed-citation></ref><ref id="scirp.132745-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Diallo, M.B., Diallo, A.T., Sow, K.B., Guirassy, S., Bald&amp;#233;, S. and Bald&amp;#233;, A. (2001) Les complications pr&amp;#233;coces de l&amp;#8217;ad&amp;#233;nomectomie prostatique transv&amp;#233;sicale au service d&amp;#8217;urologie de conakry, a propos de 96 cas. &lt;i&gt;Annals of Urological&lt;/i&gt;, 35, 120-124.&lt;br&gt;https://doi.org/10.1016/S0003-4401(01)00007-9</mixed-citation></ref></ref-list></back></article>